19:52 , Oct 13, 2017 |  BC Week In Review  |  Company News

AbbVie acquires options to Turnstone immunotherapies

AbbVie Inc. (NYSE:ABBV) acquired options to license exclusive, worldwide rights to three oncolytic viral immunotherapies from Turnstone Biologics Inc. (Ottawa, Ontario), including the company’s Ad- MG1-MAGEA3 . By combining oncolytic viruses with cancer vaccines, Turnstone...
22:18 , Oct 10, 2017 |  BC Extra  |  Company News

AbbVie, Turnstone in oncolytic virus deal

AbbVie Inc. (NYSE:ABBV) acquired options to license exclusive, worldwide rights to three oncolytic viral immunotherapies from Turnstone Biologics Inc. (Ottawa, Ontario), including the company’s Ad- MG1-MAGEA3 . By combining oncolytic viruses with cancer vaccines, Turnstone...
00:49 , Sep 9, 2017 |  BioCentury  |  Strategy

Some of the parts

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. could put the industry-leading CAR T pipeline in the hands of the company best-suited to expand the cell therapies into the as-yet-elusive solid tumor space....
18:03 , Sep 1, 2017 |  BC Week In Review  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
16:28 , Aug 18, 2017 |  BC Week In Review  |  Clinical News

MAGEA3 T cell therapy safe, leads to responses in NCI study

In a study published in the...
20:51 , Aug 17, 2017 |  BC Extra  |  Clinical News

MAGEA3 T cell therapy safe, leads to responses in NCI study

In a study published in the...
21:41 , Jul 20, 2017 |  BC Innovations  |  Product R&D

Eureka moment for TCR mimics

In the race to access the wealth of intracellular molecular targets once considered undruggable, Eureka Therapeutics Inc. is pioneering TCR -like antibodies that capitalize on the ability of TCRs to recognize tumor antigens. But the...
20:05 , May 19, 2017 |  BC Week In Review  |  Clinical News

Turnstone begins Phase I/II NSCLC trial of viral therapy

Turnstone Biologics Inc. (Ottawa, Ontario) began the Phase I/II Sandpiper trial of its adenovirus expressing melanoma-associated antigen A3 (MAGEA3)/MG1 Maraba virus expressing MAGEA3 (MG1-MAGEA3) plus Keytruda pembrolizumab to treat metastatic non-small cell lung cancer (NSCLC)...
19:57 , Jan 13, 2017 |  BC Week In Review  |  Company News

Kite, Fosun deal

Kite and Fosun formed the JV Fosun Pharma Kite Biotechnology Co. Ltd. (Shanghai, China) to develop Kite's lead chimeric antigen receptor (CAR) T cell immunotherapy candidate, axicabtagene ciloleucel (KTE-C19), in China. The JV may also...
19:56 , Jan 13, 2017 |  BC Week In Review  |  Company News

Kite, Daiichi Sankyo deal

Kite granted Daiichi Sankyo rights in Japan to develop and commercialize chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (KTE-C19). Kite will receive $50 million up front and is eligible for up to $200...